Georgia Banjo, a health writer for The Economist, and Michael Nedelcovych, a pharmaceuticals analyst at TD Cowen, dive into the booming market of weight-loss drugs. They discuss how these medications not only promise to revolutionize health outcomes for over a billion people suffering from obesity but also have immense economic implications. With companies like Novo Nordisk and Eli Lilly leading the charge, they explore market trends, pricing challenges, and the potential reshaping of societal views on health and body image. A fascinating look at the intersection of health and economics!
